RxC International

Commercialization Imperatives for Success in Rare Diseases

Commercialization Imperatives for Success in Rare Diseases

Published in Pharmaceutical Executive on September 13, 2019

To ensure patients have timely access to expensive new therapies, biopharma companies have to address commercialization challenges with innovative measures.

Best Practices in Global Commercialization to Optimize Brand Potential

Best Practices in Global Commercialization to Optimize Brand Potential

What are the critical areas of focus for commercial planning to successfully launch biopharma products in today’s environment? What are the best practices in commercialization? How to maximize brand value at launch and during its life cycle? Learn about RxC International’s approach and how we are supporting commercialization efforts in biopharma.

Value of Disease Leadership for Biopharma Companies in Today's Environment

Value of Disease Leadership for Biopharma Companies in Today's Environment

What does it take to establish disease leadership? Why is it so challenging to attain? Learn about RxC International’s approach and the core components of disease strategy to maximize value for biopharma companies in today’s environment.

Driving Innovation of BioPharma Products Through Life Cycle Planning

Driving Innovation of BioPharma Products Through Life Cycle Planning

Given the challenges to consistently innovate in drug research and the clinical risks associated with drug development, it’s imperative for biopharma companies to maximize the value of every product by institutionalizing an effective life cycle management approach”, said Nick DeSanctis, Executive Partner at RxC International, a life sciences management consulting firm in New Jersey.